Janus kinase (JAK) inhibitors are a group of medications that can treat various types of arthritis, including rheumatoid arthritis (RA), cancer, dermatological conditions like atopic dermatitis and ...

CREATE DOMAIN creates a new domain. A domain is essentially a data type with optional constraints (restrictions on the allowed set of values). The user who defines a domain becomes its owner. If a ...

In Silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité − Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, ...

A new BLA for Dato-DXd targets EGFR-mutated NSCLC, following withdrawal of a previous application based on ... alterations who have progressed on or after one regimen of platinum-based chemotherapy ...

Non-small cell lung carcinoma (NSCLC) comprises 80%–85% of lung cancer cases. EGFR is involved in several cancer developments, including NSCLC. The EGFR pathway regulates the Bax/Bcl-2 cascade in ...

Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia, may be driven by endothelial cell-cycle acceleration via CDK6, suggesting potential for repurposing CDK6 ...

甲磺酸瑞齐替尼（ BPI-7711， 瑞必达） 是倍而达药业研发的不可逆、高选择性的第三代小分子 EGFR 抑制剂，对 EGFR 突变体 （如 EGFR T790M、L858R）具有不可逆抑制作用。 2024 年 5 月，瑞齐替尼首次在国内获批，用于既往经 EGFR-TKI 治疗时或治疗后出现疾病进展 ...

(B) (C) Attractive electrostatic interaction between PKR-E375 (blue) and K3-L45 (yellow) in the AlphaFold2 model of PKR bound to K3. (C) Surface structure of the PKR kinase domain with sites colored ...